Champions Oncology (formerly Champions Biotechnology) is hoping to win big in the field of cancer research. Its Champions Tumorgraft platform allows the company to implant human tumors of various cancer types into mice, allowing scientists to study the effects of investigational drugs on human cancers. The company uses the platform in its own research and also provides tumor-specific research to doctors, as well as the Tumorgraft platform to other drug developers. The company has licensed the rights to explore Irinophore, a nanoparticle in preclinical development.